THE POTENCY OF SOURSOP LEAF WATER EXTRACT ON ACTIVATING GLP-1R, INHIBITING DPP4 AND FOXO1 PROTEIN BASED ON IN SILICO ANALYSIS
Objective: Soursop leaf contains alkaloids, terpenoids, flavonoids, acetogenin, and phenolics. Soursop leaf decoction is usually consumed as an anti-obesity agent, even though its active compounds and its action mechanism are still unclear. Computational approaches have been developed to predict the ability of an active compound to bring about biological effects. This study was designed to predict the potency of soursop (Annona muricata Linn.) water extract for the activating of Glucagon-Like Peptide-1 Receptor (GLP-1R), Inhibiting Dipeptidyl Peptidase 4 (DPP4), and Forkhead Box Protein O1 (FoxO1) protein using in silico analysis.
Methods: Identification of active compounds contained in soursop leaf water extract was carried out using physicochemical methods and Gas chromatography–mass spectrometry (GC-MS). They were then analyzed using computational analysis, i.e., potential analysis using the Way2drug web server. Protein interaction predictions of GLP-1R with the active compounds found in soursop leaf water extract using STITCH. The affinities of the active compounds of soursop leaf to the proteins DPP4 and FoxO1 were also analyzed using molecular docking.
Results: Active compounds of the soursop leaf water extract contain 5-isopropenyl-3,8-dimethyl-1,2,3,3A, 4,5,6,7-octa hydro azulene (22.17%) and 1,2-benzene dicarboxylic acid, diethyl ester (phthalic acid) (57.30%). The active ingredients have not been shown to interact with GLP-1R. 5-isopropenyl-3,8-dimethyl-1,2,3,3A, 4,5,6,7-octa hydro azulene and phthalic acid both have a weak affinity for DPP4, and only phthalic acid has a weak affinity with the FoxO1 protein.
Conclusion: Phthalic acid has a weak potential as an inhibitor of the DDP4 and FoxO1 proteins.
2. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 2014;4:1-10.
3. Elfahmi, Woerdenbag HJ, Kayser O. Jamu: Indonesian traditional herbal medicine towards rational phytopharmacological use. J Herb Med 2014;69:1-23.
4. Morton, Julia F. The Soursop, Or Guanabana (Annona Muricata). Florida Atlantic University; 1966. p. 355-66.
5. Nwokocha CR, Owu DU, Gordon A, Thaxter K, McCalla G, Ozulua RI, et al. Possible mechanisms of action of the hypotensive effect of Annona muricata (soursop) in normotensive sprague-dawley rats. Pharm Biol 2012;50:1436-41.
6. Florence NT, Benoit MZ, Jonas K, Alexandra T, Desire DD, Pierre K, et al. Antidiabetic and antioxidant effects of annona muricata (Annonaceae), aqueous extract on streptozotocin-induced diabetic rats. J Ethnopharmacol 2014;151:784-90.
7. Ishola IO, Awodele O, Olusayero AM, Ochieng CO. Mechanisms of analgesic and anti-inflammatory properties of annona muricata linn. (Annonaceae) fruit extract in rodents. J Med Food 2014;17:1375-82.
8. Cercato LM, White PA, Nampo FK, Santos MR, Camargo EA. A systematic review of medicinal plants used for weight loss in Brazil: is there potential for obesity treatment? J Ethnopharmacol 2015;176:286-96.
9. George V Cijo. Antioxidant, DNA protective efficacy and HPLC analysis. J Food Sci Technol 2015;52:2328–35.
10. Agbai EO, Njoku CJ, Nwanegwo CO, Nwafor A. Effect of aqueous extract of Annona muricata seed on atherogenicity in streptozotocin-induced diabetic rats. Afr J Pharm Pharmacol 2015;9:745-55.
11. Patel S, Patel JK. A review on a miracle fruits of Annona muricata. J Pharmacogn Phtochem 2016;5:137-48.
12. Pai BHM, Rajesh G, Shenoy R, Rao A. Anti-microbial efficacy of soursop leaf extract (Annona muricata) on oral pathogens: an in vitro study. J Clin Diagn Res 2016;10:ZC01-ZC04.
13. Bikomo EO, Ebuehi OAT, Magbagbeola A. Antidepressant activity of ethanol leaf extract of annona muricata L, in spraque-dawley rats. Am J Biochem 2017;7:1-5.
14. Yajid AI, Ab Rahman HS, Wong MPK, Zain WZW. Potential benefits of annona muricata. Malays J Med Sci 2018;25:5-15.
15. Moghadamtousi SZ, Fadaeinasab M, Nikzad S, Mohan G, Ali HM, Kadir HA. Annona muricata (Annonaceae): a review of its traditional uses, isolated acetogenins and biological activities. Int J Mol Sci 2015;16:15625-58.
16. Nik Mat Daud MM, Yaakob H, Mohamad Rosdi MN. Acetogenins of annona muricata leaves: characterization and potential anticancer study. Integr Cancer Sci Therap 2016;3:543-51.
17. James WP. WHO recognition of the global obesity epidemic. Int J Obes 2008;32(Suppl 7):S120–S126.
18. Segula D. Complications of obesity in adults: a short review of literature. Malawi Med J 2014;26:20-4.
19. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists. Diabetes Care 2011;34(Suppl 2):S279-S282.
20. Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab 2014;16:9-21.
21. Harbener JF, Kiefer TJ. Glucagon and glucagon like peptides. In: Joslin’s Diabetes Mellitus. 14th edition. Editor. CR Kahn, GL King, AC Moses, GC Weir, AM Jacobson, RJ Smith. Philadelphia: Lippincott Willams and Wilkins; 2005. p. 179-90.
22. Sandoval DA, Dalessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 2015;95:513-48.
23. Donnelly D. The structure and function of glucagon-like peptide-1 and its ligands. Br J Pharmacol 2012;166:27–41.
24. Druker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010;33:428-33.
25. Van Bloemendaal L, Ten Kulve JS, Ia Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 2014;221:T1-16.
26. Reimann F, Gribble FM. Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion. J Diabetes Investigation 2016;7(Suppl 1):13-9.
27. Buteau J, Spatz ML, Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 2006;55:1190-6.
28. Fusco J, Xiao X, Prasadan K, Sheng Q, Chen C, Ming YC. GLP-1/Exendin-4 induces ?-cell proliferation via the epidermal growth factor receptor. Sci Rep 2017;7:1-6.
29. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005;24:7410-25.
30. Kitamura T, Ido Kitamura Y. Role of FoxO proteins in pancreatic beta cells. Endocr J 2007;54:507-15.
31. Kitamura YI, Kitamura T, Kruse JP, Raum JC, Stein R, Gu W, et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab 2005;2:153-63.
32. Okamoto H, Hribal ML, Lin HV, Bennett WR, Ward A, Accili D. Role of the forkhead protein FoxO1 in beta cell compensation to insulin resistance. J Clin Invest 2006;116:775-82.
33. Gross DN, Van den Heuvel AP, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene 2008;27:2320-36.
34. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic ?-cell dedifferentiation as mechanism of diabetic ?-cell failure. Cell 2012;150:1223-34.
35. Wadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. In silico drug design: An approach which revolutionarised the drug discovery process. OA Drug Design Delivery 2013;1:3.
36. De Ruyck J, Brysbaert G, Blossey R, Lensink MF. Molecular docking as a popular tool in drug design, an in silico travel. Adv Appl Bioinform Chem 2016;9:1-11.
37. Félix Silva J, Souza T, Menezes YA, Cabral B, Camara B, Camara RB, et al. Aqueous leaf extract of Jatropha gossypiifolia L. (Euphorbiaceae) inhibits enzymatic and biological actions of bothrops jararaca snake venom. PLoS One 2014;9:e104952.
38. Oyedeji O, Taiwo FO, Ajayi OS, Ayinde F, Oziegbe M, Oseghare CO. Biocidal and phytochemical analysis of leaf extracts of annona muricata (Linn.). Int J Sci: Basic Appl Res 2015;24:76-87.
39. Ezhilan BP, Neelamegam R. GC-MS analysis of phytocomponents in the ethanol extract of polygonum chinense L. Pharmacognosy Res 2012;4:11-4.
40. Szklarczyk D, Santos A, Von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data. Nucleic Acids Res 2016;44:D380–D384.
41. Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol 2015;1263:243-50.
42. Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Computer Aided Mol Des 2010;24:417–22.
43. Gallwitz B. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes diabetes. Diabetes Metab Syndr Obes 2013;6:1-9.
44. Damayanti DS, Utomo DH, Kusuma C. Revealing the potency of Annona muricata leaves extract as FOXO1 inhibitor for diabetes mellitus treatment through computational study. In Silico Pharmacol 2016;5:3.
45. Adewole SO, Ojewole JA. Protective effects of annona muricata Linn. (Annonaceae) leaf aqueous extract on serum lipid profiles and oxidative stress in hepatocytes of streptozotocin-treated diabetic rats. Afr J Traditional 2008;6:30-41.
46. Nagashima T, Shigematsu N. Maruki R, Urano Y, Tanaka H, Shimaya A, et al. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol 2010;78:961–70.
47. Zhang T, Kim DH, Xiao X, Lee S, Gong Z, Muzumdar R. FoxO1 plays an important role in regulating-cell compensation for insulin resistance in male mice. Endocrinology 2016; 157:1055–70.
This work is licensed under a Creative Commons Attribution 4.0 International License.